[Association between visual improvement after photocoagulation and the use of angiotensin converting enzyme inhibitors in diabetic macular oedema]
- PMID: 26775057
- DOI: 10.1016/j.circir.2015.09.004
[Association between visual improvement after photocoagulation and the use of angiotensin converting enzyme inhibitors in diabetic macular oedema]
Abstract
Background: Angiotensin converting enzyme inhibitors are effective in delaying the progression of diabetic retinopathy. It is unknown if their use is associated with a better visual outcome in patients with diabetic macular oedema.
Material and methods: A non-experimental, comparative, longitudinal and retrospective study was performed on patients with diabetic macular oedema treated by focal photocoagulation, and with systemic arterial hypertension treated with angiotensin converting enzyme inhibitors (Group 1), and without hypertension (Group 2). The dependent variable was the proportion with visual improvement, operatively defined as the gain of one or more lines of vision three weeks after photocoagulation. The independent variable was the use of angiotensin converting enzyme inhibitors. The proportion of eyes with visual improvement after treatment was compared between groups using the Chi squared (χ(2)) test.
Results: A total of 33 eyes (51.6%) were assigned to group 1, and 31 (48.2%), to group 2. The mean of visual acuity improved after three weeks, compared with baseline (p=0.002). The proportion of eyes with visual improvement did not differ between patients treated with angiotensin converting enzyme inhibitors (45.5%) and those that did not use them (51.6%, p=0.4).
Conclusions: There was no statistical difference in the proportion of eyes with visual improvement between patients treated with angiotensin converting enzyme inhibitors and in those where they were not used. There is no support for the inhibition of angiotensin II in addition to photocoagulation for improving the outcome in patients with diabetic macular oedema.
Keywords: Angiotensin converting enzyme inhibitors; Diabetic macular oedema; Diabetic retinopathy; Edema macular diabético; Focal photocoagulation; Fotocoagulación focal; Inhibidores de la enzima convertidora de angiotensina; Mejoría visual; Retinopatía diabética; Visual improvement.
Copyright © 2015 Academia Mexicana de Cirugía A.C. Published by Masson Doyma México S.A. All rights reserved.
Similar articles
-
[Lack of correlation between retinal variables before treatment and poor functional response after focal photocoagulation in diabetic macular oedema].Cir Cir. 2016 Jan-Feb;84(1):3-8. doi: 10.1016/j.circir.2015.05.050. Epub 2015 Aug 12. Cir Cir. 2016. PMID: 26277600 Spanish.
-
[Efficacy of dorzolamide in reducing retinal thickness after photocoagulation in diabetic macular oedema].Cir Cir. 2015 Jan-Feb;83(1):3-8. doi: 10.1016/j.circir.2014.08.001. Cir Cir. 2015. PMID: 25982601 Clinical Trial. Spanish.
-
[Expected effect of retinal thickness after focal photocoagulation in diabetic macular oedema].Cir Cir. 2016 Sep-Oct;84(5):356-62. doi: 10.1016/j.circir.2015.09.011. Epub 2016 Jan 6. Cir Cir. 2016. PMID: 26769516 Spanish.
-
[New perspectives in the approach to diabetic macular edema. Aflibercept therapy].Arch Soc Esp Oftalmol. 2015 Mar;90 Suppl 1:24-8. doi: 10.1016/S0365-6691(15)30006-X. Arch Soc Esp Oftalmol. 2015. PMID: 25925048 Review. Spanish.
-
Pathogenesis of diabetic retinopathy and the renin-angiotensin system.Ophthalmic Physiol Opt. 2003 Nov;23(6):495-501. doi: 10.1046/j.1475-1313.2003.00134.x. Ophthalmic Physiol Opt. 2003. PMID: 14622351 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical